Monday, April 28, 2025

4:50 PM - 5:30 PM

Carron 1

---

Details

Join us for an interactive case study discussion with international experts on the treatment of myelofibrosis (MF). This event will highlight the considerations of patient outcomes and treatment goals when selecting JAK inhibitors (JAKi) for MF and sharing their thoughts on challenging cases in line with the SmPC. Don't miss this opportunity to gain valuable insights and network with experts in the field. This promotional symposium is organised and funded by Novartis Pharmaceuticals UK, Ltd, intended for UK healthcare professionals only. Prescribing Information will be available at the meeting for all Novartis brands mentioned. The speakers have been offered an honorarium for their involvement in this programme. UK | March 2025 | FA-11352217-1 Adverse Event Reporting: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

---

Speaker